Skip to content
Peptigraph home

ENLIGHTEN-1: Eloralintide Phase 3 trial (NCT07321886)

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, Without Type 2 Diabetes

Registry record checked

At a glance

Phase
Phase 3
Status
Recruiting
Enrolment
1,980
estimated
Start
6 Feb 2026 (actual)
Primary completion
Mar 2028 (estimated)
Sponsor
Eli Lilly and Company
Design

Arms and doses

NCT07321886 study arms
ArmTypeInterventionsDescription
Eloralintide Dose 1ExperimentalDrug: EloralintideParticipants will receive eloralintide subcutaneously (SC)
Eloralintide Dose 2ExperimentalDrug: EloralintideParticipants will receive eloralintide SC
Eloralintide Dose 3ExperimentalDrug: EloralintideParticipants will receive eloralintide SC
Eloralintide Dose 4ExperimentalDrug: EloralintideParticipants will receive eloralintide SC
PlaceboPlacebo comparatorDrug: PlaceboParticipants will receive placebo SC
Endpoints

Primary endpoint

NCT07321886 primary outcomes
MeasureTime frame
Percent Change from Baseline in Body WeightBaseline, Week 64
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT07321886 secondary outcomes
MeasureTime frame
Percent Change from Baseline in Total Body Fat MassBaseline, Week 64
Change from Baseline in Waist CircumferenceBaseline, Week 64
Percent Change from Baseline in TriglyceridesBaseline, Week 64
Change from Baseline in Systolic Blood Pressure (SBP)Baseline, Week 64
Time to Onset of Type 2 Diabetes (T2D)Baseline to Week 168 and Week 191
Change from Baseline in Body Mass Index (BMI)Baseline, Week 64
Change from Baseline in Hemoglobin A1c (HbA1c)Baseline, Week 64
Percent Change from Baseline in Fasting InsulinBaseline, Week 64
Percent Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP)Baseline, Week 64
Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)Baseline, Week 64
Change from Baseline in Short Form-36 Version 2 (SF-36 v2) ScoreBaseline, Week 64
Change from Baseline in EQ-5D-5LBaseline, Week 64
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
Not stated
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

Sources

  1. 1A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, Without Type 2 DiabetesClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.